In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC
Phase 3positiveamivantamabPositive
AI Analysis
Summary
Phase III PAPILLON study demonstrates amivantamab plus chemotherapy achieves median overall survival of 34.3 months versus 27.9 months with chemotherapy alone in first-line EGFR Exon 20 insertion-positive advanced NSCLC, representing the longest reported survival for this patient population.
Clinical Trial Data
Phase
III
Primary Endpoint
Met
Outcome Details
Median overall survival of 34.3 months with amivantamab-chemotherapy versus 27.9 months with chemotherapy alone
Importance:8/10
Sentiment:
0.85
Phase 3oncologyNSCLCamivantamabPAPILLON studyoverall survival
Read the original article
Published by PR Newswire Biotech on September 14, 2026 11:14 AM